2025 HCPCS Code C9098
Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
TAGS: ciltacabtagene directed preparation maturation leukapheresis antigen autologous therapeutic millionNotice | HCPCS C9098 terminated on September 30, 2022. |
Short Description | Ciltacabtagene car pos t |
HCPCS Action Code | N - No maintenance for this code |
HCPCS Coverage Code | C - Carrier judgment |
HCPCS Code Added Date | July 01, 2022 |
HCPCS Action Effective Date | October 01, 2022 |
HCPCS Pricing Indicator Code | 53 - Statute |
HCPCS Type Of Service Code | 1 - Medical care |
HCPCS Multiple Pricing Indicator Code | A - Not applicable as HCPCS priced under one methodology |
HCPCS Anesthesia Base Unit Quantity | 0 |
HCPCS Coverage Issues Manual Reference Section Number |
Check Similar HCPCS Codes
- C9458 - Florbetaben f18
- C9459 - Flutemetamol f18
- C9460 - Injection, cangrelor
- C9461 - Choline c 11, diagnostic
- C9462 - Injection, delafloxacin
- C9463 - Injection, aprepitant
- C9464 - Injection, rolapitant
- C9465 - Injection, durolane
- C9466 - Injection, benralizumab
- C9467 - Inj rituximab hyaluronidase
- C9468 - Inj, factor ix, rebinyn
- C9469 - Inj triamcinolone acetonide
- C9470 - Aripiprazole lauroxil im
- C9471 - Hymovis, 1 mg
- C9472 - Inj talimogene laherparepvec
- C9473 - Injection, mepolizumab
- C9474 - Inj, irinotecan liposome
- C9475 - Injection, necitumumab
- C9476 - Injection, daratumumab
- C9477 - Injection, elotuzumab